Centiva Capital’s AbbVie ABBV Stock Holding History

Centiva Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,500	Closed	-$444K	–	1486
2024 Q4	$444K	Sell	2,500 -2,500	-50%	-$460K	0.01%	899
2024 Q3	$987K	Hold	5,000	–	–	0.02%	850
2024 Q2	$858K	Hold	5,000	–	–	0.01%	851
2024 Q1	$911K	Sell	5,000 -22,500	-82%	-$3.88M	0.02%	714
2023 Q4	$4.26M	Sell	27,500 -17,000	-38%	-$2.48M	0.1%	190
2023 Q3	$6.63M	Buy	44,500 +9,900	+29%	+$1.45M	0.15%	118
2023 Q2	$4.66M	Sell	34,600 -16,900	-33%	-$2.48M	0.1%	201
2023 Q1	$8.21M	Sell	51,500 -12,900	-20%	-$1.97M	0.2%	91
2022 Q4	$10.4M	Sell	64,400 -800	-1%	-$123K	0.29%	61
2022 Q3	$8.75M	Buy	65,200 +18,000	+38%	+$2.58M	0.16%	77
2022 Q2	$7.23M	Buy	47,200 +26,600	+129%	+$4.06M	0.17%	92
2022 Q1	$3.34M	Sell	20,600 -20,900	-50%	-$3.04M	0.06%	272
2021 Q4	$5.62M	Buy	41,500 +37,850	+1,037%	+$4.47M	0.12%	168
2021 Q3	$394K	Buy	+3,650	New	+$417K	0.02%	702
2021 Q1	–	Sell	-500	Closed	-$54K	–	1122
2020 Q4	$54K	Buy	+500	New	+$48K	﹤0.01%	861
2020 Q3	–	Sell	-500	Closed	-$49K	–	675
2020 Q2	$49K	Sell	500 -1,400	-74%	-$123K	﹤0.01%	614
2020 Q1	$144K	Sell	1,900 -88,800	-98%	-$7.56M	0.01%	473
2019 Q4	$8.03M	Buy	90,700 +31,400	+53%	+$2.61M	0.39%	52
2019 Q3	$4.49M	Buy	59,300 +38,700	+188%	+$2.65M	0.27%	74
2019 Q2	$1.5M	Sell	20,600 -31,700	-61%	-$2.49M	0.09%	177
2019 Q1	$4.21M	Sell	52,300 -22,400	-30%	-$1.83M	0.28%	56
2018 Q4	$6.88M	Buy	74,700 +29,800	+66%	+$2.62M	0.54%	25
2018 Q3	$4.25M	Buy	+44,900	New	+$4.26M	0.37%	43

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centiva Capital's ABBV Position: Q1 2026 in Review

Centiva Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 4,350 shares — an estimated $994K sold.

Centiva Capital first reported a position in ABBV in Q3 2018 and held it in 21 quarters. The position peaked at $5.93M in Q2 2020. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Centiva Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Centiva Capital sold 4,350 AbbVie shares in Q1 2026, an estimated $994K.
Centiva Capital first reported a position in AbbVie in Q3 2018 and held it in 21 quarters.
Centiva Capital's AbbVie position peaked at $5.93M in Q2 2020.
4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Centiva Capital's 13F filing for Q1 2026, filed 14 May 2026.